|Bid||0.2391 x 4000|
|Ask||0.2800 x 100400|
|Day's Range||0.2387 - 0.2463|
|52 Week Range||0.2100 - 2.1800|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article, I’m going to take a look at OHR Pharmaceutical Inc’s (NASDAQ:OHRP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
OHR Pharmaceutical Inc (NASDAQ:OHRP), a USD$20.01M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
A lottery ticket, however, costs only a buck or two, while getting a biotech company wrong can hurt a lot more than that. Case in point: OHR Pharmaceutical Inc (NASDAQ:OHRP) is crashing nearly 80% on Friday, after reporting that topline data from its MAKO study did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration (“wet-AMD”).
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user! China Information Technology, Inc. - Ordinary Shares ...
Shares of mological drug maker OHR Pharmaceutical Inc (NASDAQ:OHRP) are skyrocketing nearly 47% today, after Cerebral Investing published an article on Seeking Alpha explaining the merits of its long position. Key points made in the article hinge on the high probability of success for the company's Phase 3 clinical trial in wet AMD, the 'explosive' market opportunity, and the stock's valuation, which offers a uniquely compelling risk/reward profile for investors. Cerebral Investing stated, "OHRP is significantly mispriced at current levels given the probability of the success of its Phase 3 clinical trial, the results of which will be released in early 2018.
Ohr Pharmaceutical Inc (NASDAQ:OHRP), a pharmaceuticals, biotechnology and life sciences company based in United States, See our latest analysis for OHRP What’s the opportunity in OHRP? Good news, investors! OHRPRead More...
Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).